- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 30.03. | Reviva Pharmaceuticals: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | 264 | GlobeNewswire (Europe) | - Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia - - Current data package highlights... ► Artikel lesen | |
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 28.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 25.03. | Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split | 2 | Insider Monkey | ||
| 25.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering | 83 | GlobeNewswire (Europe) | CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that... ► Artikel lesen | |
| 23.03. | Reviva Pharmaceuticals raises $10 million in public offering | 1 | Investing.com | ||
| 23.03. | Reviva Pharmaceuticals schließt Kapitalerhöhung über 10 Millionen US-Dollar ab | 4 | Investing.com Deutsch | ||
| 19.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 19.03. | Reviva Pharmaceuticals prices $10M public offering at $1.50 | 3 | Investing.com | ||
| 19.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 18.03. | Reviva Pharmaceuticals announces proposed public offering | 1 | Seeking Alpha | ||
| 18.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering | 3 | GlobeNewswire (USA) | ||
| 05.03. | D. Boral Capital downgrades Reviva Pharmaceuticals stock rating to hold | 10 | Investing.com | ||
| 05.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 15 | SEC Filings | ||
| 23.01. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 13 | SEC Filings | ||
| 05.01. | Chardan Capital assumes coverage on Reviva Pharmaceuticals stock with Buy rating | 11 | Investing.com | ||
| 29.12.25 | Reviva Pharmaceuticals: Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum | 4 | GlobeNewswire (USA) | ||
| 24.12.25 | H.C. Wainwright bestätigt Kaufempfehlung für Reviva, senkt aber Kursziel nach FDA-Feedback | 17 | Investing.com Deutsch | ||
| 24.12.25 | Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright | 4 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 40,120 | -0,82 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.04.2026... ► Artikel lesen | |
| NOVO NORDISK | 32,075 | +0,03 % | Novo Nordisk: Neue Abnehm-Spritze setzt Maßstäbe | Novo Nordisk bringt mit Wegovy HD eine deutlich stärkere Version seiner Abnehmspritze auf den US-Markt und erzielt beeindruckende klinische Ergebnisse mit bis zu 21 Prozent Gewichtsverlust. Gleichzeitig... ► Artikel lesen | |
| ROCHE | 340,27 | -0,06 % | UBS stuft ROCHE HOLDINGS AG auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Roche mit einem Kursziel von 384 Franken auf "Buy" belassen. Währungseffekte dürften das erste Quartal deutlich belastet... ► Artikel lesen | |
| VIATRIS | 11,676 | +0,67 % | Viatris Inc.: Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 | Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands
Expecting Impactful Near-Term... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 5,780 | +1,05 % | Green Thumb Industries Inc: Green Thumb releases social impact report | ||
| TONIX PHARMACEUTICALS | 10,710 | +0,75 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and ... | Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigeminal... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 16,550 | +3,12 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| FILANA THERAPEUTICS | 1,442 | +1,12 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 2,990 | -0,99 % | Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed | HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| COMPASS PATHWAYS | 4,740 | +0,42 % | Compass Pathfinder Limited: Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026 | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,880 | -2,70 % | Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
| OPUS GENETICS | 4,560 | 0,00 % | Opus Genetics, Inc.: Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital | - Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment -- Strategic financing to accelerate development of earlier-stage... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,685 | +1,79 % | Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right | ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to... ► Artikel lesen | |
| MINDWALK | 0,915 | -1,08 % | Highflyer der Zukunft - "Must Have" für ihr Biotech-Depot?! | ||
| KAZIA THERAPEUTICS | 8,820 | -2,76 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) | Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression
SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia... ► Artikel lesen |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -8,85 % bei einem Aktienkurs von 0,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.